News | July 20, 2011

IDEV Completes Enrollment in Supera Stent Trial For Treatment of PAD

July 20, 2011 — IDEV Technologies Inc. announced the completion of enrollment in the SUPERB trial, a U.S. Food and Drug Administration (FDA)-approved IDE trial evaluating the use of IDEV's Supera stent system for treatment of peripheral artery disease (PAD) in the superficial femoral artery (SFA). Enrollment was completed in May, making SUPERB one of the fastest-enrolling SFA trials.

The trial is a prospective, single-arm study of 258 patients at 49 United States sites. It is led by national co-investigators Kenneth Rosenfield, M.D., of Massachusetts General Hospital in Boston and Lawrence Garcia, M.D., of Steward's St. Elizabeth's Medical Center of Boston. The study objective is to demonstrate safety and effectiveness of the Supera stent in treating obstructive disease in the SFA.

Rosenfield summarized, "We are excited to complete enrollment in this important trial, and will now focus our efforts on patient follow-up and analysis. Given the encouraging data we've seen from Europe for the Supera stent, and given the stent's outstanding mechanical properties, we are anxious to finalize our results. It has been a pleasure to work with the great team of researchers, coordinators, and support staff on this trial."

"Endovascular treatment of the SFA in particular has been problematic for the millions of patients suffering from PAD in the United States," added Garcia. "The unique radial strength and flexibility of the Supera stent's design may provide what has been needed to successfully treat this challenging vessel."

Dennis Donohoe, M.D., is IDEV's chief medical officer and has served as a key liaison to the clinical site investigators throughout the trial. "Completing enrollment of more than 250 pivotal patients in less than two years is a significant achievement and reflects not only the caliber of our investigator teams but also their confidence in this stent. I congratulate the team and look forward to our continued collaboration."

The Supera Veritas transhepatic biliary system currently has 510(k) clearance in the United States for the palliative treatment of biliary strictures produced by malignant neoplasms. The SUPERB trial results will be used to support IDEV's pre-market approval (PMA) submission for an additional peripheral vascular indication.

For more information: www.idevmd.com

Related Content

FDA Issues Final Guidance on Live Case Presentations During IDE Clinical Trials
News | Cardiovascular Clinical Studies | July 10, 2019
The U.S. Food and Drug Administration (FDA) issued the final guidance “Live Case Presentations During Investigational...
Veradigm Partners With American College of Cardiology on Next-generation Research Registries
News | Cardiovascular Clinical Studies | July 03, 2019
The American College of Cardiology (ACC) has partnered with Veradigm, an Allscripts business unit, to power the next...
New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
Overlay Init